Mr. Bernard Gloster:

On the screening services generally, there is an acceptance of the benefit to the population of good screening services regardless of the specific context. I know some of the services have been very challenged. Focus on the recovery of screening services post-Covid was a challenge. I have some information about fairly steady progress in recovery to steady-state for cervical, breast and bowel screening. Rapid access clinics for lung cancer and so on are all part of the bigger mix. I do not have the clinical expertise in this but I would generally favour that in a health service focused on population health needs assessment, that part of the needs assessment would be a prioritisation of the best return and value to the public of the totality of screening services. This would be measured against the prevalence of the diseases we are trying to reduce. Proactive screening and proactive engagement of people in the management of their own health is something I have a passion for. We are talking much more about the preventative and capturing stages to intervene rather than the serious damage that comes later.